Our data suggest that the effects of elevated levels of IL-36γ in COPD are likely to be greatly amplified by the reduced secretion of IL-36Ra and that blocking IL-36R may be of clinical benefit. The gene discussed is IL36G; the disease is chronic obstructive pulmonary disease.